SAN DIEGO, Aug. 10 /PRNewswire-FirstCall/ -- Favrille, Inc. , a biopharmaceutical company developing patient-specific immunotherapies for the treatment of cancer, will host a conference call and live webcast at 4:30 p.m. Eastern Time today to discuss the Company’s second quarter 2006 financial results.
(Logo: http://www.newscom.com/cgi-bin/prnh/20031013/LAM095LOGO )
John P. Longenecker, Ph.D., President and Chief Executive Officer of Favrille, will also present an update on the Company. A press release reporting Favrille’s second quarter financial results was issued earlier today.
A live audio webcast of management’s presentation will be available on the Investor Relations section of the Company’s web site at www.favrille.com. Alternatively, callers may participate in the conference call by dialing (800) 561-2718 or (617) 614-3525, passcode 63460381. A telephone replay of the call will also be available for 48 hours. The telephone replay can be accessed by dialing (888) 286-8010 or (617) 801-6888, passcode 74137894.
About Favrille, Inc.
Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company’s lead product candidate, FavId, is based upon unique genetic information extracted from a patient’s tumor. FavId is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell NHL and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost- effective manufacturing technology, including a second product candidate, FAV- 201, for the treatment of cutaneous T-cell lymphoma.
Photo: http://www.newscom.com/cgi-bin/prnh/20031013/LAM095LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comFavrille, Inc.
CONTACT: Pete De Spain, Associate Director of Favrille, Inc., InvestorRelations & Corporate Communications, +1-858-526-2426, orpdespain@favrille.com
Web site: http://www.favrille.com//
